Trial Profile
Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Omalizumab (Primary)
- Indications Food hypersensitivity; Peanut hypersensitivity
- Focus Therapeutic Use
- Acronyms COMBINE
- 15 Nov 2023 Planned End Date changed from 31 Dec 2023 to 1 Sep 2025.
- 15 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 1 Jun 2025.
- 21 Nov 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.